Asianet Newsable on MSN
Mounjaro vs Trulicity: Eli Lilly’s new FDA win puts its blockbuster weight-loss drug in focus
Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Lilly’s diabetes drug Trulicity.
Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...
When it comes to diet pills and weight loss medications, there’s no magic bullet to drop weight quick and easy. But some ...
Eli Lilly's dual GIP/GLP-1 drug, Mounjaro, has moved one step closer to receiving a cardiovascular risk reduction label following Phase 3 trial data showing that the therapy performed on par with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results